Trials / Terminated
TerminatedNCT00790101
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Female
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risedronate | |
| DRUG | Raloxifene | |
| OTHER | Placebo |
Timeline
- Start date
- 2004-06-01
- Completion
- 2004-10-01
- First posted
- 2008-11-13
- Last updated
- 2011-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00790101. Inclusion in this directory is not an endorsement.